Lan Pham
Principal Scientist II Abbvie
Seminars
Wednesday 14th October 2026
Delving Into Discovery of Pan-PI3K & mTOR Dual Inhibitors as a First-in-Class ADC Payload
9:00 am
- Breaking down rationale for pursuing PI3K inhibitor as a first-in-class payload, tackling challenges with anti-tumor potency and regression
- Spotlighting novel PI3K payload chemical structure with mTOR dual inhibition mechanism to deliver more potent and durable cytotoxic response
- Highlighting PI3K mTOR payload preclinical activity to date including in vitro mechanism of targeting pathway, efficacy in prioritised antigens and hyperglycaemia and skin toxicity safety characterization
